Semaglutide integrated effects on key body systems 3.2.1
T1D Fund portfolio company i2O Therapeutics is developing several products leveraging GLP-1s, initially for T2D, including a refillable, implantable GLP-1 device that delivers 6 months worth of the hormone, an oral form of long acting GLP-1, as well as a combined oral GLP-1 with Amylin (another important gut hormone)
It stimulates insulin secretion, reduces glucagon release, slows down digestion, and promotes a feeling of fullness after meals
reveal that GHRP-6 alone was associated with a peak growth hormone response around 60 mU/L, while the combination of GHRP-6 with full-length GHRH was reported to raise the peak to roughly 140 mU/L, or 7-fold higher than the highest physiological peaks
Lewis made the remark with a straight face and even got a chuckle out of Cohen, who had to cover his face and look away to contain himself